Buscar
Bristol-Myers Squibb Co
BMYAñadir a la lista de seguimiento
59.365USD
+1.785+3.10%
Cierre 07/13, 16:00（ET）Cotizaciones retrasadas 15 min
121.22BCap. mercado
16.62P/E TTM
Más Datos de Bristol-Myers Squibb Co Compañía
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Información de Bristol-Myers Squibb Co
Símbolo de cotizaciónBMY
Nombre de la empresaBristol-Myers Squibb Co
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoBoerner (Christopher S)
Número de empleados34100
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 17
DirecciónRoute 206 And Province Line Road
CiudadPRINCETON
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal08543
Teléfono16092524621
Sitio Webhttps://www.bms.com
Símbolo de cotizaciónBMY
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoBoerner (Christopher S)
Ejecutivos de Bristol-Myers Squibb Co
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Mr. Michael R. (Mike) McMullen
Mr. Michael R. (Mike) McMullen
Independent Director
Independent Director
1.00K
--
Mr. Peter J. (Pete) Arduini
Mr. Peter J. (Pete) Arduini
Independent Director
Independent Director
--
--
Mr. Theodore R. Samuels, II
Mr. Theodore R. Samuels, II
Lead Independent Director
Lead Independent Director
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
146.89K
+56.50%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
34.08K
+60.04%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
28.79K
+5.61%
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
28.48K
+2.00%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
13.13K
+15.73%
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
1.20K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bristol-Myers Squibb Co?
Los cinco principales accionistas de Bristol-Myers Squibb Co son: Dr. Christopher S. (Chris) Boerner, Ph.D.
¿Cuántas instituciones poseen acciones de Bristol-Myers Squibb Co (BMY)?
A fecha de 2026Q1, 4176 instituciones poseen acciones de Bristol-Myers Squibb Co, con un valor de mercado combinado de aproximadamente 1.72B, lo que representa el 84.35% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -11351598.00.
¿Cuál es la mayor fuente de ganancias de Bristol-Myers Squibb Co?
El 2026Q1, el segmento empresarial Eliquis generó la ganancia más alta para Bristol-Myers Squibb Co, ascendiendo a 14.44B y representando el 29.97% de la ganancia total.